GlaxoSmithKline Pharmaceuticals Limited · NSE:GLAXO
GlaxoSmithKline Pharmaceuticals — Investor Presentation (2006)
9 slides from GlaxoSmithKline Pharmaceuticals's investor presentation, 2006
Slide 1: Analysts Meet 2006
Analysts Meet 2006 N
Slide 2: Highlights: 2006
Highlights :2006 z Parit reaches no.5 position amongst Rabiprazole brands. z Windamet becomes the leading brand amongst Rosiglitazone/Metformin combinations. z Windia at no.4 position amongst Rosiglitazone brands. z Plans to launch Carvidelol, a second generation antibiotic, Arixtra, possibly Tykerb
Slide 3: Financials 2006
Financials 2006 Jan - Dec 05 Jan - Dec 06 Change Rs. L. % to Sales Rs. L. % to Sales Rs. L. % to Sales 1575,89 Sales 1677,57 90,59 Less: Excise Duty on Sales 124,65 1485,30 100.0 Net Sales 1552,92 100.0 67,62 4.6 32,19 Other Income 46,52 14,33 10,00 Treasury Income 15,06 5,06 23,45 Interest income 3
Slide 4: Growth in 2006
Growth in 2006 (continuing business) In INR Mn Sales 14,901 9.3 Gross Margin 8,984 12.2 Opex (8.0) 4,468 Other Income 465 45.0 Treasury Income 494 47.5 PBT 5,474 20.6
Slide 5: Financials 2006 (continuing businesses)
Financials 2006 (continuing businesses) Jan - Dec 05 Jan - Dec 06 Change Rs. L. % to Sales Rs. L. % to Sales Rs. L. % to Sales 1454,49 Sales 1614,72 90,59 Less: Excise Duty on Sales 124,65 1363,90 100.0 Net Sales 1490,07 100.0 126,17 9.3 32,19 Other Income 46,52 14,33 10,00 Treasury Income 15,06 5,0
Slide 6: Segmental Performance
Segmental Performance Sales Rs. Mn 13732 629 866 302 15529 Growth % 9.2 (48.2) 8.7 10.4 4.6 Continuing businesses Growth % 9.3 36% 34% PBT margins 32% 31% 25% 25% 24% 24% 20% 2006 14% 2005 Pharma AFC QFC Exports Overall Profit Rs. Mn 4529 86 218 73 5560 Growth % 21.0 (48.6) 8.8 9.2 16.3 Continuing b
Slide 7: Exceptional
Exceptional In INR Mn Actuals Actuals 2006 2005 Govt. demand / provision for Pricing (28) (176) (Zevit / Salbutamol formulations) Profit on sale of AFC business 1,870 - Expenses incidental to sale of AFC business (7) Share Buyback - (19) Property Sale - 2,166 Compulsory deductible under flood - (4)
Slide 8: Strong financial performance
Strong financial performance EPS and Book Value per share 160.0 42.7 45.0 35.7 40.0 140.0 30.5 35.0 120.0 24.4 30.0 100.0 17.3 25.0 Book value 80.0 ` 142 20.0 EPS 60.0 112 106 15.0 90 40.0 78 10.0 20.0 5.0 0.0 0.0 2002 2003 2004 2005 2006 25.0% PAT % to Sales 35.0% Return on Net Worth % 23% 20.0% 30
Slide 9: End of Presentation
End of Presentation
GlaxoSmithKline Pharmaceuticals — Investor Presentation (2006) on 6ix